Cover Image
Market Research Report

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028

Published by GlobalData Product code 325931
Published Content info 153 Pages
Delivery time: 1-2 business days
Price
Back to Top
Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028
Published: April 30, 2020 Content info: 153 Pages
Description

Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche's Avastin, and epidermal growth factor receptor (EGFR) inhibitors.

GlobalData valued the CRC market at $6.4B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $8.1B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.4%. This global growth is driven by the anticipated approval and launch of 9 pipeline therapies and label expansion of other agents, but will likely be tempered by marked generic erosion of the majority of the currently marketed branded therapies available in 2018.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
  • The rapidly growing aging population will lead to an increase in the CRC incident case in the markets covered in this report. Overall, the diagnosed incident cases of CRC across the 8MM are expected to increase by an Annual Growth Rate (AGR) of 1.9% from 2018-2028.
  • GlobalData found that there is a large unmet need for the identification of new targets and biomarkers to guarantee the optimal integration of current and future therapies into the treatment paradigm and to improve patient outcomes.

KEY QUESTIONS ANSWERED

  • Nine late-stage pipeline agents are going to enter the mCRC market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in mCRC and which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of metastatic colorectal cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline metastatic colorectal cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting metastatic colorectal cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global metastatic colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global metastatic colorectal cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global metastatic colorectal cancer cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global metastatic colorectal cancer therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Product Code: GDHC182PIDR

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Colorectal Cancer: Executive Summary

  • 2.1 CRC Market is Expected to Grow to $8.1B in 2028
  • 2.2 Avastin to Remain Leader despiteCompetition from Novel Mechanisms of Action
  • 2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
  • 2.4 CRC Pipeline Moving Towards Precision Medicine in Both the Early and Metastatic Setting
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems for CRC
  • 4.3 Clinical Presentation

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Sources Not Used
    • 5.4.3 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for CRC
    • 5.5.1 Diagnosed Incident Cases of CRC
    • 5.5.2 Age-Specific Diagnosed Incident Cases of CRC
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of CRC
    • 5.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis
    • 5.5.5 Diagnosed Incident Cases of CRC by Molecular Markers
    • 5.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis
    • 5.5.7 Diagnosed Incident Cases of CRC by Sidedness
    • 5.5.8 Five-Year Diagnosed Prevalent Cases of CRC
    • 5.5.9 All-Time Diagnosed Prevalent Cases of CRC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Colorectal Cancer: Key Metrics in the 8MM
  • Table 2: 8MM,TNM Staging and Classification for CRC
  • Table 3: Risk Factors and Comorbid Conditions Associated with CRC
  • Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ≥18 Years, 2018
  • Table 5: CRC Disease Management Across the 8MM
  • Table 6: Treatment Guidelines for CRC
  • Table 7: Leading Treatments for mCRC, 2018
  • Table 8: Roche's CRC Portfolio Assessment, 2020
  • Table 9: Amgen's CRC Portfolio Assessment, 2020
  • Table 10: Eli Lilly's CRC Portfolio Assessment, 2020
  • Table 11: Bayer's CRC Disease Portfolio Assessment, 2020
  • Table 12: Bristol-Myers Squibb's CRC Portfolio Assessment, 2020
  • Table 13: Merck KGA's CRC Disease Portfolio Assessment, 2020
  • Table 14: Merck & Co.'s CRC Disease Portfolio Assessment, 2020
  • Table 15: Novartis's CRC Disease Portfolio Assessment, 2020
  • Table 16: Pfizer's CRC Portfolio Assessment, 2020
  • Table 17: Sanofi's CRC Portfolio Assessment, 2020
  • Table 18: Taiho's CRC Disease Portfolio Assessment, 2020
  • Table 19: CRC Market - Global Drivers and Barriers, 2018-2028
  • Table 20: Key Events Impacting Sales for CRC in the US, 2018-2028
  • Table 21: CRC Drivers and Barriers in the US, 2018-2028
  • Table 22: Key Events Impacting Sales for CRC in the 5EU, 2018-2028
  • Table 23: CRC - Drivers and Barriers in the 5EU, 2018-2028
  • Table 24: Key Events Impacting Sales for CRC in Japan, 2018-2028
  • Table 25: CRC - Global Drivers and Barriers in Japan, 2018-2028
  • Table 26: Key Events Impacting Sales for CRC in China, 2018-2028
  • Table 27: CRC - Global Drivers and Barriers in China, 2018-2028
  • Table 28: Key Historical and Projected Launch Dates for CRC
  • Table 29: Key Historical and Projected Patent Expiry Dates for mCRC
  • Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for CRC in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in CRC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage CRC Pipeline Agents
  • Figure 4: Diagram of the Cancers of the Colon and Rectum
  • Figure 5: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ≥18 Years, 2018-2028
  • Figure 6: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ≥18 Years, 2018-2028
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC
  • Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC
  • Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases
  • Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness
  • Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ≥18 Years, 2018
  • Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 15: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ≥18 Years, 2018
  • Figure 16: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 17: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 18: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 20: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 21: Unmet Needs and Opportunities in CRC
  • Figure 22: Overview of the Development Pipeline in CRC
  • Figure 23: Key Phase II/III Trials for Promising CRC Pipeline Agents
  • Figure 24: Competitive Assessment of the Late-Stage CRC Pipeline Agents
  • Figure 25: Analysis of the Company Portfolio Gap in mCRC During the Forecast Period
  • Figure 26: 8MM, Sales Forecast by Country for CRC in 2018 and 2028
  • Figure 27: 8MM, Sales Forecast by Drug Class for CRC in 2018 and 2028
  • Figure 28: Sales Forecast by Class for CRC in the US, 2018 and 2028
  • Figure 29: Sales Forecast by Class for CRC in the EU, 2018 and 2028
  • Figure 30: Sales Forecast by Class for CRC in Japan in 2018 and 2028
  • Figure 31: Sales Forecast by Class for CRC in China in 2018 and 2028
Back to Top